Price (delayed)
$5.62
Market cap
$571.81M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.45
Enterprise value
$553.39M
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation
There are no recent dividends present for TRVI.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.